{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:14:12Z","timestamp":1744215252732,"version":"3.37.3"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CORPG6L0101"],"award-info":[{"award-number":["CORPG6L0101"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Real-world data on the effectiveness of glecaprevir\/pibrentasvir (GLE\/PIB) for patients with HCV infection and compensated cirrhosis is limited, especially for the 8-week regimen and in an Asian population. This retrospective study enrolled 159 consecutive patients with HCV and compensated cirrhosis who were treated with GLE\/PIB at a single center in Taiwan. Sustained virological response (SVR) and adverse events (AEs) were evaluated. Among the 159 patients, 91 and 68 were treated with GLE\/PIB for 8 and 12 weeks, respectively. In the per protocol analysis, both the 8- and 12-week groups achieved 100% SVR (87\/87 vs. 64\/64); and in the evaluable population analysis, 95.6% (87\/91) of the 8-week group and 94.1% (64\/68) of the 12-week group achieved SVR. The most commonly reported AEs, which included pruritus (15.4% vs. 26.5%), abdominal discomfort (9.9% vs. 5.9%), and skin rash (5.5% vs. 5.9%), were mild for the 8- and 12-week groups. Two patients in the 8-week group exhibited total bilirubin elevation over three times the upper normal limit. One of these two patients discontinued GLE\/PIB treatment after 2 weeks but still achieved SVR. Both 8- and 12-week GLE\/PIB treatments are safe and effective for patients of Taiwanese ethnicity with HCV and compensated cirrhosis.<\/jats:p>","DOI":"10.1371\/journal.pone.0272567","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T17:41:55Z","timestamp":1660844515000},"page":"e0272567","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of 8- versus 12-weeks of glecaprevir\/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting"],"prefix":"10.1371","volume":"17","author":[{"given":"Yung-Hsin","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Kuang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Hsien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Yu","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shui-Yi","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Wei","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Lin","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kao-Chi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4949-393X","authenticated-orcid":true,"given":"Wei-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1581-6948","authenticated-orcid":true,"given":"Te-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"pone.0272567.ref001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"S Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0272567.ref002","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease.","volume":"14","author":"AP Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0272567.ref003","first-page":"469","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study.","volume":"206","author":"MH Lee","year":"2010","journal-title":"J Inf Dis"},{"key":"pone.0272567.ref004","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jhep.2016.07.039","article-title":"Reversion of disease manifestations after HCV eradication","volume":"65","author":"AJ Van der Meer","year":"2016","journal-title":"J Hepatol"},{"key":"pone.0272567.ref005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"O Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"pone.0272567.ref006","unstructured":"World Health Organization. Global Hepatitis Report 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789?sequence=1 Accessed December 30, 2021."},{"key":"pone.0272567.ref007","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1038\/s41598-021-93095-x","article-title":"Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.","volume":"11","author":"KC Chang","year":"2012","journal-title":"Sci Rep"},{"key":"pone.0272567.ref008","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1111\/jgh.15546","article-title":"Effectiveness of pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: a real-world effectiveness analysis","volume":"36","author":"YJ Ding","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0272567.ref009","unstructured":"AbbVie Inc. MAVIRET (glecaprevir\/pibrentasvir) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/maviret. Accessed December 10, 2021."},{"key":"pone.0272567.ref010","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40121-021-00410-0","article-title":"Addressing HCV elimination barriers in Italy: Healthcare resource utilization and cost impact using 8 weeks\u2019 glecaprevir\/pibrentasvir therapy.","volume":"10","author":"M Andreoni","year":"2021","journal-title":"Infect Dis Ther"},{"key":"pone.0272567.ref011","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pone.0272567.ref012","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","article-title":"2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population.","volume":"119","author":"ML Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"pone.0272567.ref013","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series.","volume":"73","author":"European Association for the Study of the Liver","year":"2020","journal-title":"J Hepatol"},{"key":"pone.0272567.ref014","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: The EXPEDITION-8 trial","volume":"72","author":"RS Brown","year":"2020","journal-title":"J Hepatol"},{"key":"pone.0272567.ref015","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/liv.14412","article-title":"Taiwan is on track of accelerating hepatitis C elimination by 2025","volume":"40","author":"GH Wu","year":"2020","journal-title":"Liver Int"},{"key":"pone.0272567.ref016","doi-asserted-by":"crossref","first-page":"100237","DOI":"10.1016\/j.eclinm.2019.12.007","article-title":"Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta\u2011analysis.","volume":"18","author":"MJ Zoratti","year":"2020","journal-title":"EClinicalMedicine"},{"key":"pone.0272567.ref017","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14295","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.","volume":"40","author":"CH Liu","year":"2020","journal-title":"Liver Int"},{"key":"pone.0272567.ref018","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12072-021-10158-x","article-title":"Sofosbuvir\/velpatasvir for patients with chronic hepatitis C infection and compensated liver disease: real-world data in Taiwan.","volume":"15","author":"CH Lui","year":"2021","journal-title":"Hepatol Int"},{"key":"pone.0272567.ref019","doi-asserted-by":"crossref","first-page":"23473","DOI":"10.1038\/s41598-021-03006-3","article-title":"National registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.","volume":"11","author":"CF Huang","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0272567.ref020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","article-title":"Sofosbuvir\/velpatasvir for hepatitis C infection: real-world effectiveness and safety from a nationwide registry in Taiwan.","volume":"11","author":"PN Cheng","year":"2022","journal-title":"Infect Dis Ther"},{"key":"pone.0272567.ref021","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: An integrated analysis of HCV genotype 1\u20136 patient without cirrhosis","volume":"69","author":"M Puoti","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0272567.ref022","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1016\/j.cgh.2020.06.044","article-title":"Eight weeks of treatment with Glecaprevir\/Pibrentasvir is safe and efficacious in an integrated analysis of treatment-na\u00efve patients with hepatitis C virus infection","volume":"18","author":"E Zuckerman","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0272567.ref023","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"P Lampertico","year":"2020","journal-title":"J Hepatol"},{"key":"pone.0272567.ref024","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.3390\/jcm10225236","article-title":"Real-world experience of chronic hepatitis c-related compensated liver cirrhosis treated with glecaprevir\/pibrentasvir: a multicenter retrospective study","volume":"10","author":"PY Su","year":"2021","journal-title":"J Clin Med"},{"key":"pone.0272567.ref025","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/jgh.15337","article-title":"Is an 8\u2010week regimen of glecaprevir\/pibrentasvir sufficient for all hepatitis C virus infected patients in the real\u2010world experience?","volume":"36","author":"D Zar\u0119bska-Michaluk","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0272567.ref026","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","article-title":"Real-world clinical practice use of 8-week glecaprevir\/pibrentasvir in treatment-na\u00efve patients with compensated cirrhosis.","volume":"37","author":"P Lampertico","year":"2020","journal-title":"Adv Ther"},{"key":"pone.0272567.ref027","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s12325-020-01301-5","article-title":"Effectiveness of 8-week Glecaprevir\/Pibrentasvir for treatment-na\u00efve, compensated cirrhotic patients with chronic hepatitis C infection.","volume":"37","author":"SL Flamm","year":"2020","journal-title":"Adv Ther"},{"key":"pone.0272567.ref028","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/liv.14829","article-title":"Glecaprevir\/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry","volume":"41","author":"H Wedemeyer","year":"2021","journal-title":"Liver Int"},{"key":"pone.0272567.ref029","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/liv.14937","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry","volume":"41","author":"H Klinker","year":"2021","journal-title":"Liver Int"},{"key":"pone.0272567.ref030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20132021 update.","volume":"75","author":"European Association for the Study of the Liver, Clinical Practice Guideline Panel","year":"2021","journal-title":"J Hepatol"},{"key":"pone.0272567.ref031","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1038\/s41598-017-03589-w","article-title":"New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis","volume":"7","author":"HW Wang","year":"2017","journal-title":"Sci Rep"},{"key":"pone.0272567.ref032","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.jfma.2020.08.010","article-title":"High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir\/pibrentasvir therapy","volume":"11","author":"WM Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"pone.0272567.ref033","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"E Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0272567.ref034","doi-asserted-by":"crossref","first-page":"ofx028","DOI":"10.1093\/ofid\/ofx028","article-title":"Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection.","volume":"4","author":"CH Liu","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"pone.0272567.ref035","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.15011","article-title":"Comorbidities, concurrent medications, and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.","volume":"48","author":"CH Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T17:42:36Z","timestamp":1660844556000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0272567"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0272567","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}